Better Coronavirus Stock: Regeneron or Gilead Sciences?
Though much attention has been paid to the development of a coronavirus vaccine in the past weeks, companies that are focused on treatments are also making rapid progress. Regeneron Pharmaceuticals (NASDAQ: REGN) is working on two efforts: an antibody cocktail and the repurposing of a rheumatoid arthritis drug that it commercializes with partner Sanofi (NASDAQ: SNY). As for Gilead Sciences (NASDAQ: GILD), the U.S. Food and Drug Administration (FDA) recently granted the company emergency use authorization for its coronavirus treatment.
Beyond the coronavirus programs, both companies have full pipelines and product portfolios. The question is: If you are looking to add just one coronavirus stock to your holdings, should you choose Regeneron or Gilead?
Image source: Getty Images.
Source Fool.com
